Key result
3-MA reduces atherosclerotic plaque size and stabilizes lesions in hyperlipidemic ApoE-/- mice.
Answers are grounded in this paper and cite their sources.
A growing body of evidence demonstrates that autophagy, an evolutionarily conserved intracellular degradation process, is involved in the pathogenesis of atherosclerosis and has become a potential therapeutic target. Here we tested the effect of two inhibitors of phosphatidylinositol 3-kinase, 3-methyladenine (3-MA) and 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), commonly used as inhibitors of autophagy, in atherosclerosis in apolipoprotein E −/− mice. Systemic application of 3-MA but not LY294002 markedly reduced the size of atherosclerotic plaque and increased the stability of lesions in high-fat diet-fed mice as compared with controls. Furthermore, 3-MA had multiple atheroprotective effects, including modulating macrophage autophagy and foam cell formation and altering the immune microenvironment. Long-term treatment with 3-MA promoted oxidized low-density lipoprotein (oxLDL)-induced macrophage autophagy and suppressed foam cell formation and cell viability in vitro . Furthermore, systemic application of 3-MA promoted lipid droplet breakdown and decreased apoptosis, most likely associated with autophagy. 3-MA treatment strikingly enhanced the expression of immune-negative molecules such as interleukin 10 (IL-10), transforming growth factor β and IL-35, as well as forkhead box P3 (Foxp3), the specific transcriptional factor for regulatory T cells, but did not affect the level of proinflammatory cytokines in the arterial wall. We provide strong evidence for the potential therapeutic benefit of 3-MA in inhibiting atherosclerosis development and improving plaque stability.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2016) studied Atherosclerosis. 3-methyladenine (3-MA) and LY294002 vs. Control was evaluated on Atherosclerotic plaque size and lesion stability. Systemic 3-methyladenine (3-MA), unlike LY294002, markedly reduced atherosclerotic plaque size and increased lesion stability in high-fat diet-fed ApoE-/- mice compared with controls.
Synapse has enriched 10 related papers. Consider them for comparative context: